Document Type : Original Article
Authors
- . Mansoor Karimifar 1
- . Farah Esmaili 1
- . Amirhossein Salari 2
- . Ali Kachuei 3
- . Ziba Faragzadegan 4
- . Mozhgan Karimifar 3
1 Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Rheumatology, Baghiyatollah University of Medical Sciences, Tehran, Iran
3 Department of Endocrinology, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Community and Preventive Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Objective: Previous studies on bone mineral density (BMD) abnormalities associated with
hypothyroidism are scarce and not conclusive. The effect of thyroid hormone therapy on
BMD has shown mixed results. The aim of the present study was to determine the severities
of osteoporosis in female patients with hypothyroidism in comparison to healthy women.
Methods: This cross‑sectional descriptive study was performed on 150 women aged
over 50 years. Totally, 100 patients with primary hypothyroidism and 50 healthy subjects were
enrolled in this study and divided into three groups. GroupA, which consisted the patients who had
been recently diagnosed with primary hypothyroidism. The second group of patients diagnosed
with primary hypothyroidism for at least 2 years and was treated with levothyroxine (Group B).
The third group of healthy individuals was selected as a control group (Group C). Blood samples
were taken for the measurements of thyroid stimulating hormone (TSH), and bone densitometry
was performed to determine the BMD reported as T‑score in order to measure the severity
of osteoporosis. T‑score of the lumbar vertebra (L2‑L4) and femoral neck were measured with
dual energy X‑ray absorptiometry and were compared between the three groups. Data were
analyzed by SPSS using regression analysis and Mann–Whitney, Kruskal–Wallis, or analysis of
variances statistical tests. The statistical significance was set at a P < 0.05.
Findings: The average age of patients and baseline serum TSH levels in Group B was
significantly different from the other two groups (P < 0.001). T‑score of the lumbar
spine (L2‑L4) in Group B was significantly lower than the other groups (P = 0.01). The
linear regression between serum TSH levels and BMD categories were not clearly associated.
However, after removing the effect of the baseline TSH level in Group B, bone loss was
significantly greater than the other two groups (P = 0.01).
Conclusion: According to the present study, it seems that the treatment of hypothyroidism
with thyroid hormones reduces both serum levels of TSH and bone density. Hence, proper
control of this risk factor can be an effective way in prevention of osteoporosis.
Keywords
- Ross DS. Bone disease with hyperthyroidism and thyroid
hormone therapy. In Muldr JE (Ed), Upto Date. 2014; Available
from http://www.Uptodate.com/home/index.html.
2. Parle JV, Franklyn JA, Cross KW, Jones SR and Sheppard
MC et al. Thyroxine prescription in the community: Serum
thyroid stimulating hormone level assays as an indicator of
undertreatment or overtreatment. British Journal of General
Practice, 1993; 43:107-9.
3. BauerDC, EttingerB, Nevitt, MC and StoneKL. Risk for fracture
in women with low serum levels of thyroid‑stimulating
hormone. Annals of International Medicine, 2001;134: 561-8.
4. Klee GG and Hay ID. Sensitive thyrotropin assays: Analytic
and clinical performance criteria. Mayo Clinical Proceedings
1988;63:1123-32.
5. Harvey. Molecular mechanisms of thyroid hormone effects on
bone growth and function. Molecular CB, O’Shea PJ, Scott AJ,
Robson H, Siebler T, Shalet SM., Samarut J, Chassande O and
Williams GR and Genetic Metabolism 2002; 75:17-30.
6. Bassett JH and Williams GR. The molecular actions of thyroid
hormone in bone. Trends in Endocrinology and Metabolism
2003;14:356-64.
7. Ng KW, Romas E, Donnan L and Findlay DM, et al. Bone
biology. Baillieres Clinical Endocrinology and Metabolism 1997;
11:1-22.
8. Anonymous. Consensus development conference: Prophylaxis
and treatment of osteoporosis. American Journal of Medicine
1991; 90:107-10.
9. Eriksen EF, Mosekilde L and Melsen F. et al. Trabecular bone
remodeling and bone balance in hyperthyroidism. Bone 1985;
6:421-28.
10. Mosekilde L, Eriksen EF and Charles P. Effects of thyroid
hormones on bone and mineral metabolism. Endocrinology
and Metabolism Clinics in North America 1990;19:35-63.
11. Martini G, Gennari L, De Paola V, Pilli T, Salvadori S,
Merlotti D, et al. The effects of recombinant TSH on bone
turnover markers and serum osteoprotegerin and RANKL
levels. Thyroid 2008;18:455-60.
12. Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A.
Serum TSH values and risk of vertebral fractures in euthyroid
post‑menopausal women with low bone mineral density. Bone
2010;46:747-75
13. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH is a
negative regulator of skeletal remodeling. Cell 2003;115:151-62. - 14. Newland CJ, Swift PG and Lamont AC. Congenital
hypothyroidism–correlation between radiographic
appearances of the knee epiphyses and biochemical data.
Postgraduate Medical Journal 1991;67:553-6.
15. Chiesa A, Gruneiro DP, Keselman A, Heinrich JJ and
Bergada C, et al. Growth follow‑up in 100 children with
congenital hypothyroidism before and during treatment.
Journal of Pediatric Endocrinology 1994;7:211-7.
16. Kooh SW, Brnjac L, Ehrlich RM, Qureshi R, Krishnan S. Bone
mass in children with congenital hypothyroidism treated with
thyroxine since birth. Journal of Pediatrics Endocrinology and
Metabolism 1996;9:59-62.
17. Leger J, Ruiz JC, Guibourdenche J, Kindermans C,
Garabedian M, Czernichow P, et al. Bone mineral density and
metabolism in children with congenital hypothyroidism after
prolonged 1‑thyroxine therapy. Acta Paediatrica 1997;86:704-10.
18. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J,
Boyle P. Mortality after the treatment of hyperthyroidism
with radioactive iodine. New England Journal of Medicine 1998;
338:712-18.
19. Gorres G, Kaim A, Otte A, Gotze M, Muller‑Brand J. Bone
mineral density in patients receiving suppressive doses of
thyroxine for differentiated thyroid carcinoma. European
Journal of Nucleic Medicine 1996;23:690-2.
20. Marcocci C, Golia F, Vignali E, PincheraA. Skeletal integrity in
men chronically treated with suppressive doses of 1‑thyroxine.
Journal of Bone Mineral Research 1997;12:72-7.
21. Ribot C, Tremollieres F, Pouilles JM. Louvet JP. Bone mineral
density and thyroid hormone therapy. Clinical Endocrinology
1990;33:143-53.
22. Schneider DL, Barrett‑Connor EL, Morton DJ. Thyroid
hormone use and bone mineral density in elderly men.
Archives of International Medicine 1995;155:2005-2007.
23. Coindre JM, David JP, Riviere L, Goussot JF, Roger P, De
Mascarel A, Meunier PJ. Bone loss in hypothyroidism with
hormone replacement. A histomorphometric study. Archives
of International Medicine 1986;146:48-53.
24. Amashukeli M, Giorgadze E, Tsagareli M, Nozadze N,
Jeiranashvili N. The impact of thyroid diseases on bone
metabolism and fracture risk. Amashukeli M, Giorgadze E,
Georgian Med News 2010;(184‑185):34‑9.
25. Kulak CA, Dempster DW. Bone histomorphometry: A
concise review for endocrinologists and clinicians. Arq Bras
Endocrinol Metabol 2010; 54:87‑98.
26. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD,
Leese GP et al. Serum thyroid‑stimulating hormone
concentration and morbidity from cardiovascular disease and
fractures in patients on long‑term thyroxine therapy. J Clin
Endocrinol Metab 2010;95:186‑93.
27. Williams GR. Actions of thyroid hormones in bone.
Endokrynol Pol. 2009; 60:380‑8.
28. Ch’ng CL, Jones MK, Kingham JG, et al. Celiac disease and
autoimmune thyroid disease. Clin Med Res 2007;5:184‑92.
29. Bassett JH, Williams AJ, Murphy E, Boyde A, Howell PG,
Swinhoe R, et al. A lack of thyroid hormones rather than
excess thyrotropin causes abnormal skeletal development in
hypothyroidism. Mol Endocrinol 2008;22:501‑12
30. Zamrazil V. Subclinical thyroid diseases. Vnitr Lek
2007;53 (7‑8):795‑8.
31. Vestergaard P, Mosekilde LThyroid, et al. Fractures in patients
with hyperthyroidism and hypothyroidism: A nationwide
follow‑up study in 16,249 patients 2002;12:411‑9.
32. Biondi, B, Cooper, DS. The clinical significance of subclinical
thyroid dysfunction. Endocr Rev 2008;29:76.
33. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol
Metab Clin North Am 2007 36:399‑419.
34. Tsai KS, Lai SM, Huang KM, Chieng PU, Su CT, Chen FW.
Decreased bone mineral density in patients with prolonged
thyrotoxicosis before and after treatment. J Formos Med Assoc
1991;90:250-5.
35. Bayley TA, Harrison JE, McMeill KG, Mernagh JR. Effect of
thyrotoxicosis and its treatment on bone mineral and muscle
mass. J Clin Endocrinol Metab 1980;50:916-22.
36. Dhanwal D, Gupta N. Bone mineral density trends in Indian
patients with hyperthyroidism after medical therapy. J Assoc
Physicians India 2011;59:561‑2, 567.
37. Tárraga López PJ, López CF, de Mora FN, Montes JA,
Albero JS, Mañez AN, CasasAG. Osteoporosis in patients with
subclinical hypothyroidism treated with thyroid hormone.
Clin Cases Miner Bone Metab 2011; 8:44-8.
38. Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R.
The relationship between serum TSH and bone mineral
density in men and postmenopausal women: The Tromsø
study. Thyroid 2008; 18:1147-55.
39. Demartini AdeA, Kulak CA, Borba VC, Cat MN, Dondoni RS,
Sandrini R, et al. Bone mineral density of children and
adolescents with congenital hypothyroidism. Arq Bras Endocrinol
Metabol 2007; 51:1084-92.
40. Nagata M, SuzukiA, Sekiguchi S, Ono Y, Nishiwaki‑Yasuda K,
Itoi T, et al. Subclinical hypothyroidism is related to lower heel
QUS in postmenopausal women. Endocr J 2007; 54:625-30.
41. Dhanwal DK, Dennison EM, Harvey NC, Cooper C. et al.
Epidemiology of hip fracture: Worldwide geographic
variation. Indian J Orthop 2011; 45:15-22
42. Dhanwal DK, Cooper C, Dennison EM. Geographic
variation in osteoporotic hip fracture incidence: The growing
importance of Asian influences in coming decades. J Osteoporos
2010; 757102.
)